Clinical Trials
138 trialsNCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT05564377 2026-05-27
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06124157 2026-05-27
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06820463 2026-05-27
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT05067283 2026-05-26
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT06469944 2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06997497 2026-05-26
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03715933 2026-05-22
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
NCT05464030 2026-05-22
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono
Phase 1 Recruiting
NCT06317662 2026-05-22
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06998940 2026-05-22
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06598007 2026-05-19
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04421820 2026-05-18
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06835387 2026-05-18
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06948448 2026-05-18
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07409272 2026-05-18
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
NCT05863195 2026-05-15
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT07415031 2026-05-15
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT05355701 2026-05-14
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT07265674 2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
NCT07432295 2026-05-14
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT06696768 2026-05-13
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06205485 2026-05-12
NEO-RT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT05647122 2026-05-11
EGRET
AstraZeneca
Phase 1 Recruiting
NCT06792695 2026-05-11
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT07283939 2026-05-11
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Alliance for Clinical Trials in Oncology
Phase NA Recruiting
NCT07554521 2026-05-11
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
BeOne Medicines
Phase 2 Recruiting
NCT05379595 2026-05-08
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05677490 2026-05-08
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06662786 2026-05-08
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-05-08
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07318805 2026-05-08
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Recruiting
NCT03801876 2026-05-07
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
Phase 3 Recruiting
NCT03959085 2026-05-05
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting
NCT05365581 2026-05-05
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT06941857 2026-05-05
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07228832 2026-05-05
HARMONi-GI3
Summit Therapeutics
Phase 3 Recruiting
NCT02981628 2026-05-04
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
NCT06958328 2026-05-04
LAP100
NRG Oncology
Phase 3 Recruiting
NCT07562711 2026-05-01
CLEAR-02
Fudan University
Phase 2 Recruiting
NCT07214298 2026-04-30
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT07559760 2026-04-30
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
The First Hospital of Jilin University
Phase 2 Recruiting
NCT06901531 2026-04-29
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT06846346 2026-04-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06385925 2026-04-24
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2 Recruiting
NCT06483555 2026-04-23
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07412613 2026-04-22
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase 3 Recruiting
NCT07543744 2026-04-22
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
Phase 1 Recruiting